
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
National report - Patients continue to seek relief and cures for skin maladies through a variety of sources, including general practitioners, home remedies, mass-media marketing and research enhanced by the Internet.